ERBB2 and breast cancer: To overcome this issue, and to categorise these tumours in the two main groups used in clinical practice (positive vs. negative), current guidelines consider BC samples as HER2-positive by IHC testing if there is an aggregate population of amplified cells composing > 10% of the total tumour cell population [4].